Abstract |
A phase II study of vindesine (VDS) was carried out in 21 patients with non-small cell lung cancer (NSCLC). There were 13 and 8 patients with and without prior chemotherapy, respectively. VDS was administered at a weekly iv dose of 3 mg/m2. Partial response was observed in two of 15 adenocarcinomas and one of 2 adenosquamous cell carcinomas, and the overall response rate was 14.3% (3/21). Myelosuppression, especially leukopenia, was the most common dose-limiting side effect. Neurotoxicity was also a common side effect but the degree was mild. It was concluded that VDS at a dose of 3 mg/m2 every week seems to be active against NSCLC.
|
Authors | J Fujita, N Saijo, K Eguchi, T Shinkai, K Tominaga, Y Sasaki, H Futami, M Sakurai, J Ishihara, H Takahashi |
Journal | Japanese journal of cancer research : Gann
(Jpn J Cancer Res)
Vol. 76
Issue 9
Pg. 902-5
(Sep 1985)
ISSN: 0910-5050 [Print] Japan |
PMID | 2997097
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adenocarcinoma
(drug therapy)
- Aged
- Carcinoma, Small Cell
(drug therapy)
- Carcinoma, Squamous Cell
(drug therapy)
- Drug Evaluation
- Female
- Humans
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Neoplasm Metastasis
- Time Factors
- Vindesine
(adverse effects, therapeutic use)
|